Legato Capital Management’s Cytokinetics CYTK Stock Holding History

Legato Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$747K	Sell	11,334 -20,614	-65%	-$1.31M	0.07%	381
2025 Q4	$2.03M	Buy	31,948 +14,345	+81%	+$892K	0.17%	187
2025 Q3	$967K	Buy	+17,603	New	+$725K	0.11%	298
2024 Q3	–	Sell	-4,380	Closed	-$237K	–	585
2024 Q2	$237K	Buy	+4,380	New	+$264K	0.03%	511
2024 Q1	–	Sell	-15,636	Closed	-$1.31M	–	577
2023 Q4	$1.31M	Buy	+15,636	New	+$566K	0.17%	192
2023 Q2	–	Sell	-14,038	Closed	-$494K	–	588
2023 Q1	$494K	Sell	14,038 -2,897	-17%	-$118K	0.09%	360
2022 Q4	$776K	Buy	+16,935	New	+$729K	0.15%	240

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Legato Capital Management's CYTK Position: Q1 2026 in Review

Legato Capital Management reduced its Cytokinetics (CYTK) stake by 65% in Q1 2026, selling an estimated $1.31M and leaving 11,334 shares worth $747K. The position accounts for 0.07% of the portfolio, ranked #381.

Legato Capital Management first reported a position in CYTK in Q4 2022 and has held it in 7 quarters since. The position peaked at $2.03M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Legato Capital Management held 11,334 shares of Cytokinetics worth $747K as of Q1 2026.
Legato Capital Management sold 20,614 Cytokinetics shares in Q1 2026, an estimated $1.31M.
Cytokinetics made up 0.07% of Legato Capital Management's portfolio in Q1 2026, its #381 holding.
Legato Capital Management first reported a position in Cytokinetics in Q4 2022 and has held it in 7 quarters since.
Legato Capital Management's Cytokinetics position peaked at $2.03M in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.